Small Cap Feast
Small Cap Feast – 25 September 2019
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Joiners Today
No Joiners Today
What’s Cooking in the IPO Kitchen?
Elektron Technology (EKT) 55p £102.3m
Elektron Technology Plc, is pleased to announce that, further to its announcements of 31 July 2019 and 3 September 2019 in respect of the Proposed Transaction (sale of Elektron Technology), the Proposed Transaction is now complete and the Group has received all monies due from Equistone Partners Europe Limited.
Following adjustments for net debt, debt-like items and working capital, the total consideration received was £104.7m. After deducting the expenses incurred in connection with the Proposed Transaction and the settlement of the LTIP liability, the net proceeds receivable approximately £94m.
As previously announced, the Board expects to return approximately £81m to shareholders by way of a tender offer for two ordinary shares for every three ordinary shares held at a price of 65 pence.
Ideagen PLC (IDEA) 149p £329m
Ideagen PLC (AIM:IDEA), a supplier of integrated risk management software to organisations in highly regulated industries, is pleased to announce excellent progress relating to the Redland Solutions Ltd business acquired in June 2019.
Since the acquisition, Redland has performed strongly securing nine new logo wins with a combined contract value of £1.2m, including prestigious clients such as Natixis, Alexander Hall, TPICAP and IG Group.
All new contract wins are for the supply of ‘Insight’, Redland’s leading Senior Management and Compliance Regime (SMCR) software and have significantly increased the Redland SMCR customer base to 49 from 40 at the time of acquisition.
600 Group PLC (SIXH) 18.1p £21.3m
The 600 Group PLC the diversified industrial engineering company (AIM: SIXH), is pleased to announce the following trading update ahead of its AGM today:
Whilst most of our markets remain subject to current global economic and political uncertainty, trading in the current financial year continues to be in line with the Board’s expectations.
Control Micro Systems (‘CMS’), acquired towards the end of June 2019, has integrated well with the Group’s existing laser activities. As part of the integration process, the management team has been strengthened and its sales and marketing functions significantly enhanced through combination with the Group’s established sales and marketing platform. The acquisition of CMS is highly complementary to the Group’s existing laser business.
Immotion Group PLC (IMMO) 6.85p £19.6m
Immotion Group, the UK-based immersive ‘Out of Home’ entertainment group, is pleased to announce agreements for three further installs in its fast growing Aquarium sector. The first of which is with Dubai Aquarium, sited in the largest shopping mall in the World, the Dubai Mall, which boasts over 80m visitors per annum. Immotion will install an initial four headsets in the Dubai Mall just outside the entrance of the Dubai Aquarium, one of the largest suspended aquariums in the World with over 140 species, including the largest collection of Sand Tiger Sharks in the World.
The two additional installs, four headsets each, are in Texas; the first at San Antonio Aquarium, and the second Austin’s Aquarium.
These new additions will all feature the ‘Ocean Explorer’ series of experiences, including the latest experience from Immotion; ‘Shark Dive’ – a live action VR experience where users can get up close with Tiger and Hammerhead Sharks.
Europa Oil & Gas (EOG) 2.05p £9.1m
Europa Oil & Gas, the oil and gas exploration, development and production company with assets in the UK, Morocco and Ireland notes the statement released yesterday by the Irish Offshore Operators’ Association (‘IOOA’), which includes clarification received from the Government of Ireland that existing exploration licences will be unaffected by the announcement by An Taoiseach Leo Varadkar on 23 September 2019. This set out the Irish Government’s intention to phase out oil exploration licences in the future. The Government has confirmed that its proposals ‘will relate to future applications’ and that ‘existing licences will remain valid’.
Amphion Innovations (AMP) SUSPENDED
Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that the Company has agreed to amend the terms under the loan facility with the Company’s debt provider as originally announced on 5 June 2014 and following the most recent amendment announced on 1 April 2019.
The Lender has agreed to extend the maturity date of the Loan Facility to 30 September 2020. No other terms have been amended.
Amryt Pharma PLC (AMYT) 131.8p £70.7m
Amryt, a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases, announced that Amryt has successfully completed the acquisition of Aegerion Pharmaceuticals, Inc. As part of the process the scheme of arrangement to insert a new UK holding company for the group yesterday became effective and the consideration for the Acquisition has been satisfied through the issue of ordinary shares of 6 pence each in the Company to stakeholders of Aegerion.
Sigma Capital Group (SGM) 104p £93m
Sigma, the private rented sector, residential development and urban regeneration specialist, announced that it has agreed terms for a major new Collaboration Agreement with Springfield Properties plc, a leading housebuilder in Scotland. The Agreement targets the delivery of hundreds of new rental homes for Sigma, focusing on five cities in Scotland – Dundee, Edinburgh, Inverness, Perth and Stirling.
The move follows the launch of the Sigma Scottish PRS Fund, which is the first dedicated vehicle to focus on the creation of new homes for the private rental market in Scotland. As previously reported, the Scottish Government’s Building Scotland Fund is supporting the Fund, which will have an initial £43m to deploy.
Mercia Asset Mgt (MERC) 31.3p £95m
Mercia Asset Management, the proactive, regionally focused specialist asset manager, is pleased to confirm that its portfolio company OXGENETM, formally known as Oxford Genetics, has augmented its relationship with one of the world’s leading global life science companies, Abcam.
This expanded agreement, which follows an earlier deal announced in August 2018, will see OXGENE deliver at least 1,000 engineered cell lines over the next three years to support Abcam.
Randall & Quilter (RQIH) 185p £362m
Accredited Surety & Casualty Company, Inc., the Florida-headquartered US insurance company that is licensed to write admitted P&C business throughout the US, has had its A.M. Best Group rating of A- (Excellent) affirmed and its financial size rating upgraded to IX ($250-$500m) from VIII.
Accredited Insurance (Europe) Limited and its UK Branch also benefits from the enhanced rating from A.M. Best
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.